rs863224007
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM1PP3_ModeratePP5_Very_Strong
The NM_000143.4(FH):c.1189G>A(p.Gly397Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000062 in 1,613,636 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000143.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FH | NM_000143.4 | c.1189G>A | p.Gly397Arg | missense_variant | 8/10 | ENST00000366560.4 | NP_000134.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FH | ENST00000366560.4 | c.1189G>A | p.Gly397Arg | missense_variant | 8/10 | 1 | NM_000143.4 | ENSP00000355518.4 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152144Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251386Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135850
GnomAD4 exome AF: 0.00000616 AC: 9AN: 1461492Hom.: 0 Cov.: 31 AF XY: 0.00000688 AC XY: 5AN XY: 727046
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152144Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74316
ClinVar
Submissions by phenotype
not provided Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jan 30, 2023 | The frequency of this variant in the general population, 0.000004 (1/251386 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in multiple unrelated individuals with hereditary leiomyomatosis and renal cell cancer (HLRCC) (PMID: 12761039 (2003), 24441663 (2014), 21630274 (2011), 21398687 (2011), 31636096 (2020), 19967458 (2010), 201618355 (2011), 19183173 (2009)) and papillary renal cell cancers (pRCC) (PMID: 25790038 (2015), 26900816 (2016)). Functional assays found reduced fumarase activity (PMID: 12761039 (2003), 21398687 (2011)). This pathogenic variant is also known as p.G354R (c.1060G>A) in the literature. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is deleterious or benign. Based on the available information, this variant is classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 22, 2023 | Observed in the heterozygous state in multiple unrelated patients with Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) and tumor studies consistent with pathogenic variants in this gene (Alam et al., 2003; Badeloe et al., 2009; Alrashdi et al., 2010; Smit et al., 2011; Kovac et al., 2015; Trpkov et al., 2016; Chan et al., 2019; Pivovarcikova et al., 2019; Casey et al., 2020); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); Also known as c.1060G>A, p.(Gly354Arg); This variant is associated with the following publications: (PMID: 20618355, 19183174, 25790038, 19967458, 28748451, 31162287, 26900816, 31636096, 31842557, 21398687, 33938658, 21445611, 12761039, 35971132, 34189567) - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 27, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 397 of the FH protein (p.Gly397Arg). This variant is present in population databases (no rsID available, gnomAD no frequency). This missense change has been observed in individual(s) with hereditary leiomyomatosis and renal cell cancer (HLRCC) (PMID: 12761039, 19967458, 20618355, 21398687). It has also been observed to segregate with disease in related individuals. This variant is also known as c.1060G>A (p.Gly354Arg). ClinVar contains an entry for this variant (Variation ID: 214422). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FH protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects FH function (PMID: 21398687). For these reasons, this variant has been classified as Pathogenic. - |
Hereditary leiomyomatosis and renal cell cancer Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Jul 06, 2023 | This variant is considered pathogenic. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 19967458, 20618355, 12761039, 16237213, 21398687, 31831373, 24441663]. This variant is expected to disrupt protein structure [Myriad internal data]. - |
Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Jul 09, 2021 | - - |
Pathogenic, no assertion criteria provided | research | Department of Traditional Chinese Medicine, Fujian Provincial Hospital | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Jan 17, 2017 | - - |
Fumarase deficiency Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | 3billion | May 22, 2022 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: <0.001%). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.82; 3Cnet: 0.99). Functional studies provide evidence of the variant reducing the FH enzymatic activity by ~50% in peripheral blood lymphocytes (PMID: 21398687) Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence for an allelic disorder, autosomal dominant Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) (OMIM: 150800) (ClinVar ID: VCV000214422). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 03, 2024 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 26, 2024 | The p.G397R pathogenic mutation (also known as c.1189G>A), located in coding exon 8 of the FH gene, results from a G to A substitution at nucleotide position 1189. The glycine at codon 397 is replaced by arginine, an amino acid with dissimilar properties. This pathogenic mutation has been reported in numerous individuals diagnosed with HLRCC or the MCUL (multiple cutaneous and uterine leiomymata) phenotype (Alam NA et al. Hum. Mol. Genet. 2003 Jun;12:1241-52; Badeloe S et al. Br. J. Dermatol. 2009 Mar;160:707-9; Alrashdi I et al. Fam. Cancer. 2010 Jun;9:239-43; Smit DL et al. Clin. Genet. 2011 Jan;79:49-59; Bardella C et al. J Pathol, 2011 Sep;225:4-11; Chen YB et al. Am J Surg Pathol, 2014 May;38:627-37; Trpkov K et al. Am J Surg Pathol, 2016 07;40:865-75; Casey RT et al. Clin Cancer Res, 2020 01;26:391-396). In one study, roughly 50% of FH enzymatic activity in peripheral blood lymphocytes was seen in two out of four French HLRCC patients who carry this FH mutation (Gardie B et al. J. Med. Genet. 2011 Apr;48:226-34). In addition, the p.G397R alteration is predicted to destabilize the local structure and protein-protein interactions of the FH protein (internal Ambry structural data). Of note, this pathogenic mutation is also known as p.G354R (c.1060G>A) in the literature. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at